BSE Live
Jan 16, 12:10Prev. Close
1186.45
Open Price
1181.35
Bid Price (Qty.)
1190.90 (5)
Offer Price (Qty.)
1190.95 (7)
NSE Live
Jan 16, 12:10Prev. Close
1186.50
Open Price
1184.00
Bid Price (Qty.)
1190.80 (130)
Offer Price (Qty.)
1190.90 (63)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 84.40 | 84.20 | 84.09 | 83.96 | 38.35 | |
| Total Share Capital | 84.40 | 84.20 | 84.09 | 83.96 | 38.35 | |
| Reserves and Surplus | 5,830.20 | 5,174.90 | 4,727.72 | 4,289.40 | 2,223.79 | |
| Total Reserves and Surplus | 5,830.20 | 5,174.90 | 4,727.72 | 4,289.40 | 2,223.79 | |
| Total Shareholders Funds | 5,914.60 | 5,259.10 | 4,811.80 | 4,373.36 | 2,262.14 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 6.30 | 8.60 | 9.73 | 8.79 | 9.61 | |
| Deferred Tax Liabilities [Net] | 96.30 | 113.10 | 105.50 | 74.91 | 70.98 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 102.60 | 121.70 | 115.23 | 83.71 | 80.60 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 556.90 | 631.70 | 452.58 | 321.11 | 914.26 | |
| Trade Payables | 1,194.30 | 780.00 | 613.28 | 598.49 | 523.79 | |
| Other Current Liabilities | 253.20 | 270.20 | 67.58 | 58.55 | 29.47 | |
| Short Term Provisions | 339.40 | 294.80 | 601.38 | 522.97 | 174.70 | |
| Total Current Liabilities | 2,343.80 | 1,976.70 | 1,734.81 | 1,501.13 | 1,642.23 | |
| Total Capital And Liabilities | 8,361.00 | 7,357.50 | 6,661.85 | 5,958.19 | 3,984.96 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,250.40 | 1,145.60 | 932.91 | 627.54 | 506.06 | |
| Intangible Assets | 65.20 | 65.20 | 54.50 | 54.50 | 55.75 | |
| Capital Work-In-Progress | 745.40 | 411.20 | 245.71 | 280.61 | 112.92 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 2,061.00 | 1,622.00 | 1,233.13 | 962.65 | 674.73 | |
| Non-Current Investments | 2,652.70 | 1,865.10 | 2,080.71 | 966.99 | 911.36 | |
| Deferred Tax Assets [Net] | 21.30 | 22.70 | 18.64 | 17.17 | 17.90 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 4,735.00 | 3,509.80 | 3,332.48 | 1,946.81 | 1,603.99 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 897.40 | 735.10 | 640.93 | 487.58 | 443.10 | |
| Trade Receivables | 1,060.50 | 1,419.70 | 897.71 | 1,055.70 | 581.22 | |
| Cash And Cash Equivalents | 368.00 | 384.40 | 537.34 | 1,456.71 | 650.94 | |
| Short Term Loans And Advances | 1,300.10 | 1,308.50 | 1,253.38 | 1,011.38 | 705.71 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 3,626.00 | 3,847.70 | 3,329.36 | 4,011.38 | 2,380.97 | |
| Total Assets | 8,361.00 | 7,357.50 | 6,661.85 | 5,958.19 | 3,984.96 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 2,016.10 | 1,934.80 | 1,892.55 | 1,896.92 | 2,409.27 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 486.40 | 553.80 | 658.48 | 380.33 | 233.11 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 110.70 | 135.50 | 77.18 | 68.63 | 41.34 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 424.30 | 491.60 | 335.36 | 301.24 | 190.52 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 3,013.80 | 2,892.50 | 2,259.91 | 2,848.33 | 1,196.66 | |
| Other Earnings | 147.60 | 230.80 | 106.83 | 244.19 | 13.35 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 17.49 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 360.10 | 53.00 | 1.92 | 1.20 | 1.16 | |
| Non-Current Investments Unquoted Book Value | 2,652.40 | 1,864.80 | 2,080.41 | 966.68 | 911.05 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
16.01.2026
15.12.2025
12.12.2025
25.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz